Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 304

1.

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E.

J Clin Oncol. 2005 Sep 1;23(25):5960-72. Epub 2005 Aug 8.

PMID:
16087945
2.

Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.

Hudis CA, Vogel CL, Gralow JR, Williams D; Procrit Study Group.

Clin Breast Cancer. 2005 Jun;6(2):132-42.

PMID:
16001991
3.

Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.

Littlewood TJ, Nortier J, Rapoport B, Pawlicki M, de Wasch G, Vercammen E, Schuette W, Wils J, Freund M; Epoetin Alfa Study Group.

Hematol Oncol. 2003 Dec;21(4):169-80.

PMID:
14735555
4.

Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy.

Bajetta E, Vercammen E, Reinhardt U, Janmohamed R, da Costa RM, Matulonis U, Guastalla JP; Epoetin Alfa Study Group.

Tumori. 2004 Sep-Oct;90(5):449-57.

PMID:
15656327
5.

Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.

Voravud N, Sriuranpong V, Suwanrusme H.

J Med Assoc Thai. 2007 Jun;90(6):1082-8.

PMID:
17624200
6.

Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer.

Hoskin PJ, Robinson M, Slevin N, Morgan D, Harrington K, Gaffney C.

J Clin Oncol. 2009 Dec 1;27(34):5751-6. doi: 10.1200/JCO.2009.22.3693. Epub 2009 Nov 2.

PMID:
19884550
7.

Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.

Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma L, Scherhag A, Burger HU.

J Clin Oncol. 2008 Feb 1;26(4):592-8. doi: 10.1200/JCO.2007.11.5378.

PMID:
18235117
8.

Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.

Chang J, Couture F, Young S, McWatters KL, Lau CY.

J Clin Oncol. 2005 Apr 20;23(12):2597-605. Epub 2004 Sep 27. Erratum in: J Clin Oncol. 2005 Aug 1;23(22):5276.

PMID:
15452188
9.

Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.

Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L.

Oncologist. 2004;9(1):90-6. Erratum in: Oncologist. 2004;9(2):240.

10.

Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial.

Grote T, Yeilding AL, Castillo R, Butler D, Fishkin E, Henry DH, DeLeo M, Fink K, Sullivan DJ.

J Clin Oncol. 2005 Dec 20;23(36):9377-86.

PMID:
16361638
11.

Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.

Provenzano R, Bhaduri S, Singh AK; PROMPT Study Group.

Clin Nephrol. 2005 Aug;64(2):113-23.

PMID:
16114787
13.

Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy.

Cortesi E, Mancuso A, De Pasquale Ceratti A, Pizzardi N, D'Auria G, Accettura C, Beccaglia P, Bertelletti D, De Marinis F.

Oncologist. 2004;9(4):459-68.

14.

Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R, Morton RF.

J Clin Oncol. 2005 Apr 20;23(12):2606-17. Epub 2004 Sep 27.

PMID:
15452187
16.

A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.

Ariganello O, Mancuso A, Di Molfetta M, Diana F, Beccaglia P, Cortesi E, De Marinis F.

Lung Cancer. 2004 Oct;46(1):119-24.

PMID:
15364140
17.

Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.

Cartenì G, Giannetta L, Ucci G, De Signoribus G, Vecchione A, Pinotti G, Puglisi F, Contillo A, Pezzella G, Orecchia S, Beccaglia P; OBI/EPO-ITA-01/1 study group.

Support Care Cancer. 2007 Sep;15(9):1057-66. Epub 2007 Apr 13.

PMID:
17431689
19.

Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.

Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U; PROTOS Study Investigators.

Clin J Am Soc Nephrol. 2007 Jul;2(4):637-46. Epub 2007 May 23.

20.

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.

Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL, Bowers PJ; Proactive Study Group.

Gastroenterology. 2004 May;126(5):1302-11.

PMID:
15131791

Supplemental Content

Support Center